Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

JP Morgan's Chris Schott raised their price target on Teva Pharmaceutical Industries (NYSE: TEVA) by 7.7% from $26 to $28 on 2025/11/07. The analyst maintained their Strong Buy rating on the stock.

Teva reported its Q3 2025 earnings.

Schott said the quarter's results were "solid."

Earnings Report

For Q3 2025, Teva reported:

• EPS of $0.78, which beat the Zacks Consensus Estimate of $0.68 and Q3 2024 by 14%.
• Revenue of $4.48B, which beat the Zacks Consensus Estimate of $4.35B and was up 3% Y/Y.

For FY 2025, management guided:

• Revenue of $16.8B to $17B, down at the top end from the prior $16.8B to $17.2B.

President & CEO Richard Francis commented: “Our innovative portfolio driving the 11th consecutive quarter of growth in the third quarter reflects the accelerating momentum of our transformation and the strength of our innovation-led Pivot to Growth strategy.

"Our key growth drivers—particularly our innovative medicines—delivered a 33% increase in local currency, underscoring their impact on both patient outcomes and our financial performance.

"As we continue executing our strategy, we remain firmly on track to reach our 30% non-GAAP operating profit margin by 2027 and ~$700 million of net savings target.

“Following the conclusion of the IRA pricing negotiations, we are reiterating our strong confidence in our AUSTEDO 2027 target.

"Our differentiated innovative portfolio is now a defining strength for Teva as we transform into a leading innovative biopharma, while our world-class generics business continues to provide a resilient foundation.

"With our talented team and unwavering commitment to patients, we are confident about Teva’s future and our ability to deliver enduring value to all our stakeholders.”